Standout Papers
Citation Impact
Citing Papers
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
2003 StandoutScienceNobel
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
2005
Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti–CTLA-4 Therapy
2011 StandoutNobel
Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin
2013 StandoutNobel
Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer
2013
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Multiple Antitumor Mechanisms Downstream of Prophylactic Regulatory T-Cell Depletion
2010 StandoutNobel
Combination Therapy with Anti–CTL Antigen-4 and Anti-4-1BB Antibodies Enhances Cancer Immunity and Reduces Autoimmunity
2006
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3 + CD25 + CD4 + regulatory T cells
2005 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Endogenous 4-1BB Ligand Plays a Critical Role in Protection from Influenza-Induced Disease
2009
Target-conditioned diffusion generates potent TNFR superfamily antagonists and agonists
2024 StandoutScienceNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
2007
Inflammation and cancer
2002 StandoutNature
Hepatocellular carcinoma
2018 Standout
The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancer
2008
Targeting death-inducing receptors in cancer therapy
2007
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells
2002
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains
2019 StandoutNatureNobel
Human ADAR1 Prevents Endogenous RNA from Triggering Translational Shutdown
2018 StandoutNobel
Chemokines: agents for the immunotherapy of cancer?
2002
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Eradication of established tumors in mice by a combination antibody-based therapy
2006
Regulatory T Cells in Cancer
2010
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
The role of myeloid cells in the promotion of tumour angiogenesis
2008
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
1998 StandoutNature
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
2010
Evaluating the Cellular Targets of Anti-4-1BB Agonist Antibody during Immunotherapy of a Pre-Established Tumor in Mice
2010
Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease
2005
Optimising anti‐tumour CD8 T‐cell responses using combinations of immunomodulatory antibodies
2008
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
2016
Antitumour actions of interferons: implications for cancer therapy
2016
Delivery technologies for cancer immunotherapy
2019 Standout
Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival
2019
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules
2005
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Genetic profiling of hepatocellular carcinoma using next-generation sequencing
2016
Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review
2015
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
2007
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
2021
Systemic treatment of hepatocellular carcinoma: An EASL position paper
2021
Immune regulation by 4‐1BB and 4‐1BBL: complexities and challenges
2009
Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production
2011 StandoutNobel
4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms
2006
Long-Term Expansion of Functional Mouse and Human Hepatocytes as 3D Organoids
2018 StandoutNobel
Combination cancer immunotherapies tailored to the tumour microenvironment
2015
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
2016
Immunotherapy: past, present and future
2003
Spinning molecular immunology into successful immunotherapy
2002
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
2017
Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease
2002
Agonistic Anti‐4‐1BB Antibody Promotes the Expansion of Natural Regulatory T Cells While Maintaining Foxp3 Expression
2007
Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses
2002
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2022
Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function
2011
Targeting Immunosupportive Cancer Therapies: Accentuate the Positive, Eliminate the Negative
2007 StandoutNobel
4-1BB-mediated immunotherapy of rheumatoid arthritis
2004
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
2004
Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial
2020
Cancer-related inflammation
2008 StandoutNature
Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent
2007
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
2016
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
A multi-targeted approach to treating bone metastases
2014
Tumors as Organs: Complex Tissues that Interface with the Entire Organism
2010
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40
2004
Hepatocellular carcinoma
2022 Standout
Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance
2002 StandoutNobel
Functional and genetic deconstruction of the cellular origin in liver cancer
2015
Induction of Broad CD4+and CD8+T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5
2008 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
4-1BB Ligand, a Member of the TNF Family, Is Important for the Generation of Antiviral CD8 T Cell Responses
1999
Administration of Agonistic Anti-4-1BB Monoclonal Antibody Leads to the Amelioration of Experimental Autoimmune Encephalomyelitis
2002
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells
2007
Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells
2004
Marked Expansion of CD11c+CD8+ T-Cells in Melanoma-bearing Mice Induced by Anti-4-1BB Monoclonal Antibody
2007
4-1BB (CD137) Is Required for Rapid Clearance ofListeria monocytogenesInfection
2005
Immune Modulation in Cancer with Antibodies
2013 StandoutNobel
Recognition of Human Histocompatibility Leukocyte Antigen (HLA)-E Complexed with HLA Class I Signal Sequence–derived Peptides by CD94/NKG2 Confers Protection from Natural Killer Cell–mediated Lysis
1998
CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation
2011
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
2012 StandoutNobel
4-1BB Functions As a Survival Factor in Dendritic Cells
2009
The B7 Family and Cancer Therapy: Costimulation and Coinhibition
2007 StandoutNobel
Development of prophylactic and therapeutic vaccines against hepatitis C virus
2005
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
1998
A Common Inhibitory Receptor for Major Histocompatibility Complex Class I Molecules on Human Lymphoid and Myelomonocytic Cells
1997
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
2015
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
The 4-1BB Costimulation Augments the Proliferation of CD4+CD25+ Regulatory T Cells
2004
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Immune Responses in 4-1BB (CD137)-Deficient Mice
2002
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells
2003 StandoutNobel
Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis
1997 Standout
Therapeutic cancer vaccines
2015
HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation
2004 StandoutNobel
Cell-Mediated Immunity and the Outcome of Hepatitis C Virus Infection
2004
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
2014
Lack of Phenotypic and Functional Impairment in Dendritic Cells from Chimpanzees Chronically Infected with Hepatitis C Virus
2004 StandoutNobel
Ox-40 Ligand: A Potent Costimulatory Molecule for Sustaining Primary CD4 T Cell Responses
1998
Tumor-Associated Macrophages in Glioma: Friend or Foe?
2013
Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells
2002
Works of Ignacio Melero being referenced
Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
2013
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti–PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells
2015
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2016 Standout
Low Surface Expression of B7-1 (CD80) Is an Immunoescape Mechanism of Colon Carcinoma
2006
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
2020
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
2017
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Advances in immunotherapy for hepatocellular carcinoma
2021
Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway
1998
CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
2018
Structure and function of the CD94 C‐type lectin receptor complex involved in recognition of HLA class I molecules
1997
Dendritic cells delivered inside human carcinomas are sequestered by interleukin‐8
2005
Immunological landscape and immunotherapy of hepatocellular carcinoma
2015
Immunostimulatory monoclonal antibodies for cancer therapy
2007
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
1997
Evolving synergistic combinations of targeted immunotherapies to combat cancer
2015
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
2014
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells
2002
Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens
2004
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
2021
Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions
2007
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ
2010
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
2010
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
2008
In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb
2009
Therapeutic vaccines for cancer: an overview of clinical trials
2014
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
2013
NK1.1 Cells Express 4-1BB (CDw137) Costimulatory Molecule and Are Required for Tumor Immunity Elicited by Anti-4-1BB Monoclonal Antibodies
1998
Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus
2005
Cytokines in clinical cancer immunotherapy
2018
Bone-marrow-derived cell differentiation into microglia: A study in a progressive mouse model of Parkinson's disease
2007
Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses
2003
Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination
2013
Direct Effects of Type I Interferons on Cells of the Immune System
2011
CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.
2015
Intratumoral Coinjection of Two Adenoviruses, One Encoding the Chemokine IFN-γ-Inducible Protein-10 and Another Encoding IL-12, Results in Marked Antitumoral Synergy
2000
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
2013
Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy
2016
Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.
2018
Functional ambivalence of the Kp43 (CD94) NK cell-associated surface antigen.
1995
Metabolic Consequences of T-cell Costimulation in Anticancer Immunity
2019
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
2015
FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040
2019
Emerging Opportunities and Challenges in Cancer Immunotherapy
2016
Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
2017
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
2003
The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1.
1997
Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
2019